DIADIA0.38%
SPYSPY1.11%
QQQQQQ2.50%
Trending
Top trending tickerBTCBTC0.69%
STRKSTRK12.45%
ETHETH1.57%
CATCAT0.66%
DRAM5.84%
GMGM0.36%
BNKRBNKR3.95%
TSLATSLA2.13%
XLKXLK3.02%
XOMXOM2.46%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolARWRnews
Exchange: NASDAQ·Updated 07:30 PM EDT

ARWR News

News
all
press releases
Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know
In the Phase 1/2a trial, patients receiving Arrowhead’s drug saw an average 73% reduction in tau protein levels in cerebrospinal fluid after 105 days, with a maximum reduction of 85%.
Stocktwits
Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know
In the Phase 1/2a trial, patients receiving Arrowhead’s drug saw an average 73% reduction in tau protein levels in cerebrospinal fluid after 105 days, with a maximum reduction of 85%.
Stocktwits
More News
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the companys investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for Alzheimers disease and other tauopathies. These results...
Business Wire
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.
Stocktwits
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowheads upcoming supplemental new drug application (sNDA) for...
Business Wire
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimers Disease and Other Tauopathies
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowheads central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam...
Business Wire
ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near
Goldman sees biotech’s recent gains holding up despite macro pressures, supported by deal activity, clinical progress, and a more favorable regulatory backdrop.
Stocktwits
Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3B-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’
Redemplo is already approved by the U.S. Food and Drug Administration (FDA) to lower very high triglycerides in the rare condition familial chylomicronemia syndrome.
Stocktwits
ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?
ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.
Stocktwits
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the companys first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease...
Business Wire
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million...
Yahoo! Finance: News

Advertisement|Remove ads.